The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
Abbvie signs up China’s I-Mab instead of Trillium, but several other early-stage contenders are looking at the novel immuno-oncology mechanism.
A shock US rejection delays approval by at least two years and makes Abbvie, which had given up rights five years ago, look smart.
The company’s massive clinical programme with BMS-986165 is set to deliver its first pivotal data later this year.
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.